BCAL Diagnostics (ASX:BDX) EPS (Basic): A$-0.02 (TTM As of Dec. 2025)


What is BCAL Diagnostics EPS (Basic)?

BCAL Diagnostics ASX:BDX +10.96% EPS (Basic) is A$-0.02 as of Dec. 2025. The stock has 3 warning signs investors should review.

BCAL Diagnostics's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was A$-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.

BCAL Diagnostics's EPS (Diluted) for the six months ended in Dec. 2025 was A$-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.

BCAL Diagnostics's EPS without NRI for the six months ended in Dec. 2025 was A$-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

BCAL Diagnostics  (ASX:BDX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

BCAL Diagnostics EPS (Basic) Related Terms

BCAL Diagnostics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics EPS (Basic) Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
EPS (Basic)
-0.02 -0.02 -0.03 -0.02

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.02 -0.01 -0.01 -0.01

BCAL Diagnostics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

BCAL Diagnostics's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-7.241-0)/359.596
=-0.02

BCAL Diagnostics's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.917-0)/366.113
=-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of A$-0.02 mean?
BCAL Diagnostics (ASX:BDX) has a EPS (Basic) of A$-0.02 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on BCAL Diagnostics and its competitors.
Is BCAL Diagnostics' EPS (Basic) too high?
BCAL Diagnostics' current EPS (Basic) is A$-0.02.
How does BCAL Diagnostics' EPS (Basic) compare to TMO and DHR?
BCAL Diagnostics' EPS (Basic) of A$-0.02 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Diagnostics & Research company?
A good EPS (Basic) depends on the Medical Diagnostics & Research industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current EPS (Basic) is A$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current EPS (Basic) of A$-0.02. The current EPS (Basic) is A$-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current EPS (Basic) is A$-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.